Career history of Sebastien Giguere
Former positions of Sebastien Giguere
| Companies | Position | Start | End |
|---|---|---|---|
Valence Discovery, Inc.
 Valence Discovery, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Recursion Pharmaceuticals, Inc., Valence Discovery, Inc. is a Canadian company committed to unlocking the true potential of deep learning in drug design. The company is based in Montréal, Canada, and is pioneering the application of few-shot learning in drug design. Valence's AI-enabled drug design platform has been extensively validated and is currently being used to identify and design drug candidates in collaboration with industry-leading partners. The company is developing and deploying novel machine learning methods for molecular property prediction, generative chemistry, and multiparameter optimization. The company was founded by Sebastian Giguere, Prudencio Tossou, Daniel Cohen, Therence Bois, Sebastien Giguere, and Daniel Cohen has been the CEO since incorporation. Valence Discovery was acquired by Recursion Pharmaceuticals, Inc. on May 16, 2023 for $35.35 million. | Chief Executive Officer | 31/08/2018 | - |
| Founder | - | - |
Training of Sebastien Giguere
| Université Laval | Undergraduate Degree |
Statistics
International
| Canada | 3 |
Operational
| Chief Executive Officer | 1 |
| Founder | 1 |
| Undergraduate Degree | 1 |
Sectoral
| Commercial Services | 2 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 1 |
|---|---|
Valence Discovery, Inc.
Valence Discovery, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Recursion Pharmaceuticals, Inc., Valence Discovery, Inc. is a Canadian company committed to unlocking the true potential of deep learning in drug design. The company is based in Montréal, Canada, and is pioneering the application of few-shot learning in drug design. Valence's AI-enabled drug design platform has been extensively validated and is currently being used to identify and design drug candidates in collaboration with industry-leading partners. The company is developing and deploying novel machine learning methods for molecular property prediction, generative chemistry, and multiparameter optimization. The company was founded by Sebastian Giguere, Prudencio Tossou, Daniel Cohen, Therence Bois, Sebastien Giguere, and Daniel Cohen has been the CEO since incorporation. Valence Discovery was acquired by Recursion Pharmaceuticals, Inc. on May 16, 2023 for $35.35 million. | Commercial Services |
- Stock Market
- Insiders
- Sebastien Giguere
- Experience
